Clinical Trials Logo

Clinical Trial Summary

Clinical trial intended to reduce the antibiotic therapy duration in "in-hospital" patients with haematological diseases who develop fever and low white blood cell count (neutropenia).


Clinical Trial Description

The optimal duration of the empirical antimicrobial therapy (AT) in hematological patients with febrile neutropenia (FN) is unknown. The Infectious Diseases Society of America (IDSA) recommends maintaining AT at least until the neutropenia is recovered, because literally "years of experience have proven this approach to be safe and effective". This recommendation is likely to cause unnecessarily prolonged treatments, and is against the urgent need of optimizing the antimicrobial therapy proposed by IDSA. The main objective of this study is to establish whether an individualized clinical protocol is better than the standard criteria (recovery of neutropenia as the criterion to suspend the empirical AT in hematological patients with FN). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01581333
Study type Interventional
Source Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Contact
Status Completed
Phase Phase 4
Start date April 2012
Completion date June 2016

See also
  Status Clinical Trial Phase
Completed NCT03641131 - Ampholipad Real-World Data in Taiwan
Not yet recruiting NCT02806557 - Profiling Neutrophil Counts in Patients on Chemotherapy N/A
Completed NCT04914702 - Feasibility and Comparison of Continuously Monitored Vital Signs in Pediatric Patients With Cancer.
Completed NCT02728596 - S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER) N/A
Completed NCT03104595 - Management of Severe Chemotherapy-induced Neutropenia in Advanced Breast Cancer Phase 1/Phase 2
Recruiting NCT02536599 - Risk Factors & Outcomes for Clinically Documented Infections in Pediatric Cancer Patients With Fever & Neutropenia
Completed NCT02005783 - Study of Danggui Buxue Decoction in Preventing Neutropenia Phase 2
Recruiting NCT03449693 - Efficacy of Oral Supplementation With Magnesium to Reduce Febrile Neutropenia Phase 2
Recruiting NCT05149547 - mNGS Versus Blood Culture in FN
Recruiting NCT05584930 - Clusterin, Ptx3 and Pediatric Febrile Neutropenia (CluPPFeN) N/A
Completed NCT04134429 - Feasibility of Monitoring Health Data in Pediatric Patients Undergoing Chemotherapy
Recruiting NCT01684189 - Registry of Febrile Neutropenia and Invasive Fungal Infections N/A
Completed NCT00462878 - Meropenem Versus Meropenem Plus Glycopeptide in Patients With Febrile Neutropenia After Allogenic Blood Stem Cell Transplantation N/A
Completed NCT00035425 - Treatment of Neutropenic Patients With Fever Who Are Suspected to Have A Gram Positive Infection Phase 3
Recruiting NCT04948463 - Early Versus Late Stopping of Antibiotics in Children With Cancer and High-risk Febrile Neutropenia Phase 4
Recruiting NCT03740464 - Long-acting G-CSF for Febrile Neutropenia Phase 3
Not yet recruiting NCT06116734 - Lapelga vs Gastrofil Phase 3
Completed NCT00503854 - Fatigue and Symptom Burden in Low-Risk Cancer Patients Undergoing Treatment for Febrile Neutropenia
Terminated NCT02732327 - Comparative Study of Ceftazidime-Avibactam Versus Standard of Care as Therapy in Febrile Neutropenic Adults With Cancer Phase 2
Completed NCT01114165 - Value of the LightCycler® SeptiFast Test MGRADE for the Pathogen Detection in Neutropenic Hematological Patients Phase 4